or Try an Advanced Search...

    Technical Analysis for LYRA - Lyra Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.26 -5.82% -0.02
    LYRA closed down 5.82 percent on Friday, November 1, 2024, on 84 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    Earnings due: Nov 5
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical LYRA trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Calm After Storm Range Contraction -5.82%
    NR7 Range Contraction -5.82%
    Upper Bollinger Band Walk Strength -5.82%
    Inside Day Range Contraction -5.82%
    Wide Bands Range Expansion -5.82%
    Up 3 Days in a Row Strength -5.82%
    Older End-of-Day Signals for LYRA ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 19 hours ago
    Down 2 % about 19 hours ago
    Down 1% about 19 hours ago
    Rose Above Upper Bollinger Band about 22 hours ago
    Up 3% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    LYRA Chart by TradingView
    Basic chart:

    Profile

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Sinus Headache Chronic Rhinosinusitis Sinusitis

    Is LYRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 15 Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
    Sep 27 Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
    Aug 15 Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks
    Aug 14 Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
    Aug 14 Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    Jul 15 Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?
    May 21 Lyra to cut 75% of workforce in portfolio shakeup
    May 21 Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
    May 7 Jefferies cuts Lyra to hold in wake of failed Phase 3 study
    May 7 Target upgraded, CVS downgraded: Wall Street's top analyst calls
    See more LYRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.79
    52 Week Low 0.2105
    Average Volume 975,363
    200-Day Moving Average 2.15
    50-Day Moving Average 0.27
    20-Day Moving Average 0.24
    10-Day Moving Average 0.26
    Average True Range 0.02
    RSI (14) 51.22
    ADX 32.21
    +DI 22.08
    -DI 11.64
    Chandelier Exit (Long, 3 ATRs) 0.23
    Chandelier Exit (Short, 3 ATRs) 0.28
    Upper Bollinger Bands 0.28
    Lower Bollinger Band 0.21
    Percent B (%b) 0.69
    BandWidth 30.69
    MACD Line 0.00
    MACD Signal Line 0.00
    MACD Histogram 0.0045
    Fundamentals Value
    Market Cap 13.61 Million
    Num Shares 52.6 Million
    EPS -1.40
    Price-to-Earnings (P/E) Ratio -0.18
    Price-to-Sales 178.41
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.31
    Resistance 3 (R3) 0.31 0.30 0.30
    Resistance 2 (R2) 0.30 0.29 0.30 0.29
    Resistance 1 (R1) 0.28 0.28 0.27 0.27 0.29
    Pivot Point 0.27 0.27 0.26 0.26 0.27
    Support 1 (S1) 0.25 0.25 0.24 0.24 0.23
    Support 2 (S2) 0.24 0.25 0.23 0.22
    Support 3 (S3) 0.22 0.24 0.22
    Support 4 (S4) 0.21